Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ERBB-2 overexpression as a risk factor for malignant phaeochromocytomas and paraganglinomas.

Clinical endocrinology - 1 Jun 2016

Wang Weiqing, Zhong Xu, Ye Lei, Qi Yan, Su TingWei, Wei Qing, Xie Jing, Jiang Lei, Jiang Yiran, Zhou Weiwei, Cui Bin, Ning Guang

Abstract excerpt

OBJECTIVE: There are currently no good histological or molecular markers to differentiate benign from malignant phaeochromocytomas and paraganglinomas (PPGLs). Our previous cross-sectional study observed that ERBB-2 overexpression was associated with malignant PPGLs. This study aimed to evaluate the predictive value of ERBB-2 overexpression for metastasis in PPGLs in a large population. METHODS: A total of 262...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Gland Neoplasms
Share to Gene Amplification

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, erbB-2

Share to In Situ Hybridization, Fluorescence

Share to Neoplasm Metastasis

Share to Paraganglioma

Share to Pheochromocytoma

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 26749044
DOI: 10.1111/cen.13019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERBB-2 overexpression as a risk factor for malignant phaeochromocytomas and paraganglinomas.PMID 26749044Read ↗

Establishment and evaluation of a novel biomarker-based nomogram for malignant phaeochromocytomas and paragangliomas.Semantic proximity Read ↗

MAML3-fusions modulate Vascular and Immune Tumor Microenvironment and Confer High Metastatic Risk in Pheochromocytoma and ParagangliomaSemantic proximity Read ↗

Disentangling of Malignancy from Benign Pheochromocytomas/Paragangliomas.Semantic proximity Read ↗

Malignant pheochromocytoma.Semantic proximity Read ↗

What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?Semantic proximity Read ↗

Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomasSemantic proximity Read ↗

MYO5B mutations in pheochromocytoma/paraganglioma promote cancer progressionSemantic proximity Read ↗

Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and ParagangliomaSemantic proximity Read ↗

Gene Expression Profiling of Benign and Malignant PheochromocytomaSemantic proximity Read ↗

Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature.Semantic proximity Read ↗

HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomasSemantic proximity Read ↗

Identification of Potential Gene Markers and Insights into the Pathophysiology of Pheochromocytoma MalignancySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.